In this observational study we found no evidence of a population-level excess of documented somatosensory or peripheral neuropathic phenotypes after semaglutide or tirzepatide initiation; the modestly lower incidence was within the range of systematic error indicated by the negative controls.
The research question
How do neurosensory outcomes compare across metabolic treatments?
Background/Objectives
Glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide and the dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist tirzepatide, are widely used for type 2 diabetes and obesity, and trials and pharmacovigilance reports have raised concern about altered sensation and peripheral neuropathy.
Methods
Using de-identified electronic health records from a U.S. federated data network, we ascertained 14 new-onset somatosensory and peripheral neuropathic phenotypes over 12 months using diagnosis codes and physician-validated, AI-curated clinical-note concepts (positive predictive value 88.8%) among adult new users of semaglutide or tirzepatide without these phenotypes at baseline.
Results
Of 169,657 at-risk users, 40,142 (23.7%) had a newly documented phenotype, most often hypoesthesia (13.0%) and paresthesia (12.3%). Incidence rose with baseline glycated hemoglobin (HbA1c), from 19.2% below 5.7% to 33.7% at 12% or higher (Cochran–Armitage p < 0.001), and showed no consistent relation to achieved weight loss. In 35,187 propensity-score-matched pairs, GLP-1 users had a lower 12-month incidence of any phenotype than initiators of metformin, dipeptidyl-peptidase-4 inhibitors or sodium-glucose cotransporter-2 inhibitors (22.1% vs. 26.3%; relative risk [RR] 0.84, 95% CI 0.82–0.86), most markedly for polyneuropathy (RR 0.69, 0.64–0.74). Seven of nine negative-control outcomes differed between the arms, in both directions; after empirical calibration to these controls, no estimate was statistically significant (any phenotype, calibrated RR 0.85, 0.58–1.25).
Conclusions
In this observational study we found no evidence of a population-level excess of documented somatosensory or peripheral neuropathic phenotypes after semaglutide or tirzepatide initiation; the modestly lower incidence was within the range of systematic error indicated by the negative controls.
Publication type and venue follow the original nference listing. Read the original paper for full methods, analyses, and interpretation. View source listing.